2022
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular And Interventional Radiology 2022, 45: 405-412. PMID: 35119481, PMCID: PMC8940827, DOI: 10.1007/s00270-021-03031-9.Peer-Reviewed Original ResearchConceptsBlinded independent central reviewIntermediate-stage hepatocellular carcinomaDisease control rateObjective response rateProgression-free survivalDuration of responseHepatocellular carcinomaCurative treatmentRECIST 1.1Primary endpointClinical benefitControl rateEastern Cooperative Oncology Group performance status 0Response rateChild-Pugh class ARandomized phase 3 studyDual primary endpointsOverall survival eventsPerformance status 0Previous systemic treatmentPD-1 inhibitorsPortal vein thrombosisPhase 3 studyResponse Evaluation CriteriaSolid Tumors 1.1
2020
Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis
Kahn S, Julian J, Kearon C, Gu C, Cohen D, Magnuson E, Comerota A, Goldhaber S, Jaff M, Razavi M, Kindzelski A, Schneider J, Kim P, Chaer R, Sista A, McLafferty R, Kaufman J, Wible B, Blinder M, Vedantham S, Sichlau M, Vlahos A, Smith S, Thalheimer Q, Singh N, Harting R, Gocke J, Guth S, Shah N, Brady P, Schatz M, Horrow M, Markazi P, Forouzan L, Matalon T, Hertzog D, Goday S, Kennedy M, Kaplan R, Campbell T, Hartman J, Nahum E, Venkat A, Krishnamurthy V, Rectenwald J, Henke P, Eliason J, Willatt J, Escobar G, Samuels S, Katzen B, Benenati J, Powell A, Pena C, Wallach H, Gandhi R, Schneider J, Kim S, Hashemi F, Boyle J, Patel N, Verta M, Leung D, Garcia M, Blatt P, Khatri J, Epstein D, Ryan R, Sweeny T, Stillabower M, Kimbiris G, Raman T, Sierzenski P, Getto L, Dignazio M, Sierzenski P, Horvath M, Gornik H, Bartholomew J, Shishehbor M, Peacock F, Joseph D, Kim S, Mahlay N, Clair D, Lyden S, Kapoor B, McLennon G, Pierce G, Newman J, Spain J, Gill A, Hamilton A, Rizzo A, Park W, Dietzek A, Galin I, Plummer D, Hsu R, Broderick P, Keller A, Sayeed S, Slater D, Lustberg H, Akus J, Sidman R, Dhami M, Kohanski P, Bulgaru A, Dulala R, Burch J, Kapur D, Yang J, Ranson M, Wladis A, Varnagy D, Mekhail T, Winter R, Perez-Izquierdo M, Motew S, Royd-Kranis R, Workman R, Kribbs S, Hogsette G, Moore P, Thomason B, Means W, Bonsall R, Stewart J, Golwya D, Azene E, Bottner W, Bishop W, Clayton D, Gundersen L, Riherd J, Shakhnovich I, Ziegelbein K, Chang T, Sharma K, Allison S, Banovac F, Cohen E, Furlong B, Kessler C, McCullough M, Spies J, Lin J, Kaatz S, Getzen T, Miller J, Schwartz S, Kabbani L, McVinnie D, Rundback J, Manno J, Schwab R, Cole R, Herman K, Singh D, Barkama R, Patel A, Comerota A, Pigott J, Seiwert A, Whalen R, Russell T, Assi Z, Kazanjian S, Yobbagy J, Kaminski B, Kaufman A, Begeman G, DiSalle R, Thakur S, Kim P, Jacquet M, Dykes T, Gerding J, Baker C, Debiasto M, Mittleider D, Higgins G, Amberson S, Pezzuti R, Gallagher T, Schainfeld R, Wicky S, Kalva S, Walker G, Salazar G, Pomerantz B, Patel V, Kabrhel C, Iqbal S, Gangull S, Oklu R, Brannan S, Misra S, Bjarnason H, Ashrani A, Caccavale M, Fleming C, Friese J, Heit J, Kalra M, Macedo T, McBane R, McKusick M, Stockland A, Woodrum D, Wysokinski W, Verma A, Davis A, Chung J, Nicker D, Anderson B, Stein R, Weiss M, Patel P, Rilling W, Tutton S, Hieb R, Hohenwalter E, Colella M, Gosset J, White S, Lewis B, Brown K, Rossi P, Seabrook G, Guimaraes M, Selby J, McGary W, Hannegan C, Robison J, Brothers T, Elliott B, Garg N, Anderson M, Uflacker R, Schonholz C, Raney L, Greenberg C, Kaufman J, Keller F, Kolbeck K, Landry G, Mitchell E, Barton R, DeLoughery T, Kalbfleisch N, Minjarez R, Lakin P, Liem T, Moneta G, Farsad K, Fleischman R, French L, Marques V, Al−Hassani Y, Sawar A, Taylor F, Patel R, Malhotra R, Kim D, Hashemi F, Boyle J, Patel R, Padnick M, Gurley M, Cucher F, Sterrenberg R, Deepthi G, Cumaranatunge G, Bhatla S, Jacobs D, Dolen E, Gamboa P, Dean L, Davis T, Lippert J, Khanna S, Schirf B, Silber J, Wood D, McGraw J, LaPerna L, Willette P, Murphy T, Cerezo J, Dhangana R, Ahn S, Dubel G, Haas R, Jay B, Prince E, Soares G, Klinger J, Lambiase R, Jay G, Tubbs R, Beland M, Hampson C, O'Hara R, Thompson C, Beland M, Frodsham A, Gardiner F, Jaffan A, Keating L, Zafar A, Alicic R, Raabe R, Brower J, McClellan D, Pellow T, Zylak C, Davis J, Reilly M, Symington K, Seibold C, Nachreiner R, Murray D, Murray S, Saha S, Luna G, Hodgson K, McLafferty R, Hood D, Moore C, Griffen D, Hurst D, Lubbers D, Kim K, Warren B, Engel J, Suresh D, VanderWoude E, Razdan R, Hutchins M, Rounsborg T, Midathada M, Moravec D, Tilford J, Kim D, Beckman J, Razavi M, Openshaw K, Flanigan D, Loh C, Dorne H, Chan M, Thomas J, Psaila J, Ringold M, Fisher J, Lipcomb A, Oskin T, Wible B, Coleman B, Elliott D, Gaddis G, Cochran C, Natarajan K, Bick S, Cooke J, Hedderman A, Greist A, Miller L, Martinez B, Flanders V, Underhill M, Hofmann L, Sze D, Kuo W, Louie J, Hwang G, Hovsepian D, Kothary N, Berube C, Schreiber D, Jeffrey B, Schor J, Deitch J, Singh K, Hahn B, Ardolic B, Gupta S, Bashir R, Rao A, Garg M, Patil P, Zack C, Cohen G, Schmieder F, Lakhter V, Sacks D, Guay R, Scott M, Cunningham K, Sigal A, Cescon T, Leasure N, Dhurairaj T, Muck P, Knochel K, Lohr J, Barreau J, Recht M, Bhaskaran J, Brahmamdam R, Draper D, Mehta A, Maher J, Sharafuddin M, Lentz S, Nugent A, Sharp W, Kresowik T, Nicholson R, Sun S, Youness F, Pascarella L, Ray C, Knuttinen M, Bui J, Gaba R, Dobiesz V, Shamim E, Nimmagadda S, Peace D, Zain A, Palumto A, Haskal Z, Hirshon J, Richard H, Verceles A, Wong-You-Chong J, Othee B, Patel R, Iliescu B, Williams D, Gemmete J, Krishnamurthy V, Cwikiel W, Cho K, Schields J, Vellody R, Novelli P, Dasika N, Wakefield T, Rectenwald J, Henke P, Desmond J, Froehlich J, Khaja M, Hunter D, Golzarian J, Cressman E, Dotta Y, Schmiechen N, Marek J, Garcia D, Tawil I, Langsfeld M, Moll S, Mauro M, Stavas J, Burke C, Dixon R, Yu H, Keagy B, Kim K, Kasthuri R, Key N, Chaer R, Makaroun M, Rhee R, Cho J, Baril D, Marone L, Hseih M, Feterik K, Smith R, Jeyabalan G, Rogers J, Vinik R, Kinikini D, Kraiss L, Mueller M, Pendleton R, Rondina M, Sarfati M, Wanner N, Johnson S, Hopkins C, Ihnat D, Angle J, Matsumoto A, Harthun N, Turba U, Saad W, Uthlaut B, Nannapaneni S, Ling D, Sabri S, Kern J, Macik B, Hoke G, Park A, Stone J, Sneed B, Syverud S, Davidson K, Sharma A, Haskal Z, Wilkins L, Black C, Asay M, Hatch D, Smilanich R, Patten C, Brown S, Nielsen R, Alward W, Collins J, Nokes M, Geary R, Edwards M, Godshall C, Levy P, Winokur R, Sista A, Madoff D, Lee K, Pua B, DeSancho M, Milizia R, Gao J, Goday S, Kennedy M, Kaplan R, Campbell T, McLean G, Hartman J, Nahum E, Khalid S, Vedantham S, Lewis L, Saad N, Thoelke M, Pallow R, Klein S, Sicard G, Cohen D, Comerota A, Gornik H, Jaff M, Julian J, Kahn S, Kearon C, Kee S, Kindzelski A, Lewis L, Magnuson E, Razavi M, Murphy T, Vedantham S. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2020, 8: 8-23.e18. PMID: 31843251, PMCID: PMC7681916, DOI: 10.1016/j.jvsv.2019.03.023.Peer-Reviewed Original ResearchConceptsPharmacomechanical catheter-directed thrombolysisProximal deep venous thrombosisDeep venous thrombosisQuality of lifeDisease-specific QOLIliofemoral deep venous thrombosisCatheter-directed thrombolysisPhysical component summaryVenous thrombosisPCDT groupChange scoresDVT patientsQOL measuresForm Health Survey Physical Component SummaryExtent of DVTLong-term QOLAssessor-blinded randomized trialGeneral QOL measuresVenous Insufficiency EpidemiologicalAcute venous thrombosisDisease-specific QOL measuresGreater improvementThrombolysis trialsCommon femoralComponent summary
2019
Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma
Cornman-Homonoff J, Bassik N, Madoff DC. Transhepatic portal stent placement and jejunal varix embolization for management of treatment-limiting gastrointestinal bleeding in a patient with unresectable recurrent intrahepatic cholangiocarcinoma. Clinical Imaging 2019, 59: 188-191. PMID: 31837541, DOI: 10.1016/j.clinimag.2019.09.012.Peer-Reviewed Case Reports and Technical NotesConceptsRecurrent cholangiocarcinomaOnly potential cureRecurrent intrahepatic cholangiocarcinomaPoor patient outcomesUnresectable diseaseGastrointestinal bleedingChemotherapy administrationMyelosuppressive effectsTherapeutic mainstayDismal prognosisIntrahepatic cholangiocarcinomaVariceal embolizationStent placementPortal veinPatient outcomesPotential cureCholangiocarcinomaEmbolizationCytopeniasBleedingRegimenChemotherapyPatientsSurgeryPrognosis
2017
Multicenter Trial of the VenaTech Convertible Vena Cava Filter
Hohenwalter EJ, Stone JR, O’Moore P, Smith SJ, Selby JB, Lewandowski RJ, Samuels S, Kiproff PM, Trost DW, Madoff DC, Handel J, Gandras EJ, Vlahos A, Rilling WS. Multicenter Trial of the VenaTech Convertible Vena Cava Filter. Journal Of Vascular And Interventional Radiology 2017, 28: 1353-1362. PMID: 28821379, DOI: 10.1016/j.jvir.2017.06.032.Peer-Reviewed Original ResearchConceptsVena cava filtersCava filtersDevice-related adverse eventsHigh-risk traumaAdverse event ratesSingle-arm studyFailure of anticoagulationTechnical success rateLong-term safetyConverted patientsAdverse eventsPulmonary embolismSurgical prophylaxisVenous thromboembolismMulticenter trialCaval filtersRight atriumSurgical removalClinical assessmentProcedure timePatientsEvent ratesMean timeSuccess rateMonths
2014
Characterization of In Vivo Ablation Zones Following Percutaneous Microwave Ablation of the Liver with Two Commercially Available Devices: Are Manufacturer Published Reference Values Useful?
Winokur RS, Du JY, Pua BB, Talenfeld AD, Sista AK, Schiffman MA, Trost DW, Madoff DC. Characterization of In Vivo Ablation Zones Following Percutaneous Microwave Ablation of the Liver with Two Commercially Available Devices: Are Manufacturer Published Reference Values Useful? Journal Of Vascular And Interventional Radiology 2014, 25: 1939-1946.e1. PMID: 25307296, DOI: 10.1016/j.jvir.2014.08.014.Peer-Reviewed Original ResearchBland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients
2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albuminHigh Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome
Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. Journal Of Clinical Oncology 2011, 29: 1083-1090. PMID: 21263087, PMCID: PMC3068054, DOI: 10.1200/jco.2010.32.6132.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsFemaleHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyPatient SelectionRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsAdvanced colorectal liver metastasesTwo-stage resectionColorectal liver metastasesLiver metastasesComplete resectionSurvival rateMedical groupMajor postoperative complicationsSurvival of patientsChemotherapy initiationNonsurgical patientsOnly chemotherapyPostoperative complicationsColorectal metastasesMetastatic diseaseObjective responseWorse survivalTreat analysisGood respondersExcellent outcomesTSR groupInclusion criteriaResectionPatientsChemotherapy
2010
Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases
Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R. Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases. Clinical Colorectal Cancer 2010, 9: 311-314. PMID: 21208846, PMCID: PMC3088086, DOI: 10.3816/ccc.2010.n.045.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug Resistance, NeoplasmFemaleFluorouracilHepatic ArteryHumansInfusions, Intra-ArterialLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsOvarian NeoplasmsOxaliplatinPilot ProjectsSalvage TherapySurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsExtensive liver metastasesRefractory solid tumorsLiver metastasesTotal bilirubinSolid tumorsBaseline serum total bilirubinHepatic arterial infusion (HAI) oxaliplatinMedian Child-Pugh scoreAdvanced refractory malignanciesGrade 1 fatigueMedian total bilirubinRegional hepatic therapySystemic anticancer agentsChild-Pugh scoreCommon side effectsSerum total bilirubinPilot clinical trialElevated bilirubinLiver involvementPartial responseHepatic insufficiencyMedian ageRefractory malignanciesClinical trialsDisease progressionHepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver
Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver. American Journal Of Clinical Oncology 2010, 33: 474-480. PMID: 19935383, DOI: 10.1097/coc.0b013e3181b4b065.Peer-Reviewed Original ResearchConceptsHepatic arterial chemoembolizationOcular melanoma metastaticProgression-free survival durationMedian OS durationOverall survivalLactate dehydrogenase levelsMelanoma metastaticRadiologic responseLiver involvementSurvival durationOS durationDehydrogenase levelsResponse rateBaseline lactate dehydrogenase levelsHigher lactate dehydrogenase levelsMedian overall survivalTumor response rateHepatic artery chemoembolizationShorter overall survivalStable diseaseDisease stabilizationProgressive diseaseArterial chemoembolizationMost patientsPartial response
2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survivalThree Hundred and One Consecutive Extended Right Hepatectomies
Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ, Curley SA, Vauthey JN. Three Hundred and One Consecutive Extended Right Hepatectomies. Annals Of Surgery 2009, 127: 171-179. PMID: 19730239, DOI: 10.1097/sla.0b013e3181b674df.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBilirubinChildChi-Square DistributionEmbolization, TherapeuticEndpoint DeterminationFemaleHepatectomyHumansLiverLiver Function TestsLogistic ModelsMaleMiddle AgedOutcome and Process Assessment, Health CarePatient SelectionPortal VeinPostoperative ComplicationsPreoperative CareRetrospective StudiesRisk FactorsStatistics, NonparametricConceptsPreoperative portal vein embolizationPostoperative liver insufficiencySafe hepatic resectionPreoperative PVEExtended right hepatectomyLiver insufficiencyRight hepatectomyHepatic resectionPostoperative outcomesEnd pointLiver volumetryIntraoperative blood transfusionPrimary end pointSecondary end pointsLiver volume ratioPortal vein embolizationShort-term outcomesBody mass indexTotal liver volumeMultivariate logistic regressionFLR volumeFuture liverVein embolizationBlood transfusionConsecutive patientsMajor hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival
Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009, 145: 399-405. PMID: 19303988, DOI: 10.1016/j.surg.2008.10.009.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationMajor hepatic resectionPreoperative PVEPVE groupHepatic resectionPortal vein embolizationHepatocellular carcinomaPerioperative outcomesDFS ratesPerioperative deathsVein embolizationSurvival rateDisease-free survival ratesPreoperative transarterial chemoembolizationOverall postoperative complicationsRemnant liver volumeImproved perioperative outcomesOverall survival rateAmerican Joint CommitteeHepatitis B virusHepatitis C virusPerioperative mortalityPerioperative riskPostoperative complicationsOverall survival
2008
Is embolization of segment 4 portal veins before extended right hepatectomy justified?
Kishi Y, Madoff DC, Abdalla EK, Palavecino M, Ribero D, Chun YS, Vauthey JN. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008, 144: 744-751. PMID: 19081016, PMCID: PMC5901738, DOI: 10.1016/j.surg.2008.05.015.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationPortal vein embolizationPortal veinHypertrophy rateVein embolizationRight portal vein embolizationExtended right hepatectomyLiver remnant volumeMajor hepatectomyRight hepatectomyCurative hepatectomySubsequent resectionClinical outcomesRemnant volumeEmbolizationComplicationsPatientsAbsolute increaseHepatectomyUninjured liverSignificant differencesVeinSegment 2Volume gainResectionChemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases
Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases. Annals Of Surgical Oncology 2008, 15: 2765. PMID: 18636296, PMCID: PMC5901734, DOI: 10.1245/s10434-008-0035-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsEmbolization, TherapeuticFemaleFollow-Up StudiesHumansLiver NeoplasmsLiver RegenerationMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinPortal VeinPrognosisProspective StudiesSurvival RateTreatment OutcomeConceptsPortal vein embolizationColorectal liver metastasesVascular endothelial growth factorLiver metastasesLiver regenerationPreoperative chemotherapyFLR hypertrophyLiver resectionVein embolizationFuture liver remnant volumeFLR volume increaseMajor liver resectionLiver remnant volumeEffect of chemotherapyImpairs liver regenerationEndothelial growth factorConclusionPreoperative chemotherapyConcurrent bevacizumabProspective databaseRight hepatectomyPostoperative outcomesConsecutive patientsRemnant volumeBevacizumabMurine model
2007
Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases
Kamat PP, Gupta S, Ensor JE, Murthy R, Ahrar K, Madoff DC, Wallace MJ, Hicks ME. Hepatic Arterial Embolization and Chemoembolization in the Management of Patients with Large-Volume Liver Metastases. CardioVascular And Interventional Radiology 2007, 31: 299-307. PMID: 17922160, DOI: 10.1007/s00270-007-9186-3.Peer-Reviewed Original ResearchConceptsProgression-free survivalHepatic arterial embolizationGastrointestinal stromal tumorsOverall survivalNeuroendocrine tumorsRadiologic responseArterial embolizationDisease stabilizationLiver involvementLiver metastasesMajor complicationsLonger progression-free survivalLiver tumor burdenMedian overall survivalMetastatic neuroendocrine tumorsProcedure-related mortalityMajority of patientsManagement of patientsAdditional risk factorsHigh response rateStable diseaseSymptom palliationPartial responsePerformance statusProgressive diseaseSystemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival
Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. Journal Of Gastrointestinal Surgery 2007, 11: 1498-1505. PMID: 17849166, DOI: 10.1007/s11605-007-0272-2.Peer-Reviewed Original ResearchConceptsBilateral colorectal liver metastasesColorectal liver metastasesPreoperative portal vein embolizationTwo-stage hepatectomyGroup IGroup IISystemic chemotherapyLiver metastasesSurvival rateDisease-free survival ratesBackgroundTwo-stage hepatectomyDay postoperative mortalityOne-stage hepatectomyPreoperative systemic chemotherapyGroup II patientsMedian hospital stayOutcomes of patientsPortal vein embolizationTreatment of patientsSecond-stage hepatectomyPostoperative mortalityAggressive surgeryBilateral diseaseHospital stayMajor hepatectomyPortal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome
Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey J. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. British Journal Of Surgery 2007, 94: 1386-1394. PMID: 17583900, DOI: 10.1002/bjs.5836.Peer-Reviewed Original ResearchConceptsPortal vein embolizationHepatic dysfunctionStandardized FLRVein embolizationMortality rateFuture liver remnant volumePostoperative hepatic dysfunctionLiver-related complicationsLiver remnant volumeDegree of hypertrophyHospital stayMajor hepatectomyPostoperative complicationsHepatic resectionLiver resectionRemnant volumePrognostic informationPatientsComplicationsDysfunctionVolumetric evaluationResectionEmbolizationOutcomesCentPilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver
Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G. Pilot study of regional, hepatic intra‐arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer 2007, 109: 2190-2196. PMID: 17464952, DOI: 10.1002/cncr.22672.Peer-Reviewed Original ResearchConceptsDominant liver metastasisBreast carcinomaTaxane exposureLiver metastasesAntitumor activityCommon treatment-related toxicitiesHepatic intra-arterial therapyPatient underwent liver resectionCourses of paclitaxelUnderwent liver resectionMean patient ageTreatment-related toxicityHepatic arterial infusionIntra-arterial therapyProcedure-related complicationsBreast carcinoma metastaticMetastatic breast carcinomaIntra-arterial catheterPercutaneous transfemoral approachTime of treatmentHepatic infusionStable diseaseCarcinoma metastaticPaclitaxel therapyTaxane therapy
2006
Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors
Kobayashi K, Gupta S, Trent JC, Vauthey J, Krishnamurthy S, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, McRae SE, Hicks ME. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors. Cancer 2006, 107: 2833-2841. PMID: 17096432, DOI: 10.1002/cncr.22336.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationGastrointestinal stromal tumorsUse of imatinibOverall survivalOS timeLiver diseaseStromal tumorsTumor responseMetastatic gastrointestinal stromal tumorsExtensive liver involvementMedian OS timeObjective tumor responseMedian PFS timeProgression-free survivalKaplan-Meier methodMajority of patientsDurable tumor responsesExtrahepatic diseaseOS ratesRadiologic responseStable diseaseDisease stabilizationPFS timeExtrahepatic metastasesLiver involvement